GGrantIndex
← Leaderboards

Peter Kurre

Oregon Health And Science University

$7,509,533
Attributed
$7,509,533
Total exposure
5
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.1M · FY200525
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$7,509,533 · 5

By mechanism

R01$6,864,233 · 4
K08$645,300 · 1

Top collaborators

No co-investigators on record.

Most similar at Oregon Health And Science University

Same institution · by research overlap

Others in their field

Top investigators on “Hematopoietic

Research focus

HematopoieticCellsHematopoietic Stem CellsHematopoiesisInsightGene TherapyGeneticStem CellsIn VivoTransplantationPathway InteractionsBone MarrowDefectFanconi&AposS AnemiaTissuesPhenotypeEventEngraftmentHomingCandidate Disease GeneAutologousHereditary DiseaseModification

Grant awards (23)

Hematopoietic stem and progenitor cell regulation of the niche through extracellular vesicles$440,000
R01 · FY2025 · HL · contact PI
Hematopoietic stem and progenitor cell regulation of the niche through extracellular vesicles$440,000
R01 · FY2024 · HL · contact PI
Constrained Fetal Hematopoiesis and Clonal Restriction in Fanconi Anemia$640,103
R01 · FY2023 · HL · contact PI
Hematopoietic stem and progenitor cell regulation of the niche through extracellular vesicles$440,000
R01 · FY2023 · HL · contact PI
Constrained Fetal Hematopoiesis and Clonal Restriction in Fanconi Anemia$564,423
R01 · FY2022 · HL · contact PI
Hematopoietic stem and progenitor cell regulation of the niche through extracellular vesicles$440,000
R01 · FY2022 · HL · contact PI
Constrained Fetal Hematopoiesis and Clonal Restriction in Fanconi Anemia$622,503
R01 · FY2021 · HL · contact PI
Constrained Fetal Hematopoiesis and Clonal Restriction in Fanconi Anemia$532,743
R01 · FY2020 · HL · contact PI
Mitotically Stable Lentiviral Episomes for Stem Cell Gene Therapy$137,918
R01 · FY2017 · DK · contact PI
Mitotically Stable Lentiviral Episomes for Stem Cell Gene Therapy$69,982
R01 · FY2017 · DK · contact PI
Mitotically Stable Lentiviral Episomes for Stem Cell Gene Therapy$242,550
R01 · FY2016 · DK · contact PI
Mitotically Stable Lentiviral Episomes for Stem Cell Gene Therapy$242,550
R01 · FY2015 · DK · contact PI
HSC transduction in situ by cellular delivery of integrating viral vectors$366,520
R01 · FY2013 · HL · contact PI
HSC transduction in situ by cellular delivery of integrating viral vectors$441,464
R01 · FY2012 · HL · contact PI
HSC transduction in situ by cellular delivery of integrating viral vectors$92,797
R01 · FY2011 · HL · contact PI
HSC transduction in situ by cellular delivery of integrating viral vectors$385,000
R01 · FY2010 · HL · contact PI
HSC transduction in situ by cellular delivery of integrating viral vectors$385,000
R01 · FY2009 · HL · contact PI
Genetic targeting of proviral integration in stem cells$129,060
K08 · FY2009 · HL · contact PI
HSC transduction in situ by cellular delivery of integrating viral vectors$380,680
R01 · FY2008 · HL · contact PI
Genetic targeting of proviral integration in stem cells$129,060
K08 · FY2008 · HL · contact PI
Genetic targeting of proviral integration in stem cells$129,060
K08 · FY2007 · HL · contact PI
Genetic targeting of proviral integration in stem cells$129,060
K08 · FY2006 · HL · contact PI
Genetic targeting of proviral integration in stem cells$129,060
K08 · FY2005 · HL